QIAGEN N.V. Files Q2 2025 6-K Report
Ticker: QGEN · Form: 6-K · Filed: Aug 21, 2025 · CIK: 1015820
| Field | Detail |
|---|---|
| Company | Qiagen N.V. (QGEN) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: quarterly-report, sec-filing, foreign-private-issuer
Related Tickers: QGEN
TL;DR
QIAGEN (QGEN) filed its Q2 2025 6-K, check it for latest financials.
AI Summary
QIAGEN N.V. filed a Form 6-K for the quarterly period ended June 30, 2025. The filing, submitted on August 21, 2025, is a report of a foreign private issuer. The company's principal executive office is located at Hulsterweg 82, 5912 PL Venlo, The Netherlands.
Why It Matters
This filing provides an update on QIAGEN N.V.'s financial reporting for the second quarter of 2025, which is crucial for investors to assess the company's performance and financial health.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- QIAGEN N.V. (company) — Registrant
- June 30, 2025 (date) — Quarterly period end date
- August 21, 2025 (date) — Filing date
- Hulsterweg 82, 5912 PL Venlo, The Netherlands (location) — Principal executive office address
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2025.
When was this filing submitted to the SEC?
The filing was submitted on August 21, 2025.
What is QIAGEN N.V.'s fiscal year end?
QIAGEN N.V.'s fiscal year ends on December 31.
What is the company's primary business classification?
The company's Standard Industrial Classification is Biological Products (No Diagnostic Substances) [2836].
Does QIAGEN N.V. file annual reports under Form 20-F or 40-F?
QIAGEN N.V. indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 231 words · 1 min read · ~1 pages · Grade level 8.3 · Accepted 2025-08-21 17:20:49
Filing Documents
- a2025q2form6-k.htm (6-K) — 19KB
- a2025q2quarterlyreport.htm (EX-99.1) — 1195KB
- 0001015820-25-000057.txt ( ) — 1216KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. QIAGEN N.V. By s Roland Sackers Roland Sackers Chief Financial Officer Date August 21, 2025 4 Table of Contents EXHIBIT INDEX Exhibit No. Exhibit 99.1 U.S. GAAP Quarterly Report for the Period Ended June 30, 2025 5